Drug intelligence / Profile preview

TT46

Development stage: Preclinical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

TT46 is a potential DNA vaccine developed through DNA shuffling, incorporating a helper T-cell epitope from the tetanus toxin B subunit. It is being investigated for its antiangiogenic properties and its ability to enhance the efficacy of chemotherapy, specifically doxorubicin, in treating hepatocellular carcinoma (HCC). Studies in mouse models of H22 hepatocellular carcinoma have shown that TT46 vaccination can significantly reduce microvessel counts, inhibit tumor angiogenesis, and improve survival rates when combined with doxorubicin.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on TT46.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT46.

Explore the full profile